Sol-Gel Technologies Ltd Dossier
Qualitative Analysis
Business overview
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a clinical-stage specialty dermatology company focused on identifying, developing, and commercializing branded and generic topical drug products for patients with rare and severe skin conditions. The company's proprietary technology platform utilizes silica-based microencapsulation to stabilize active pharmaceutical ingredients, improving efficacy and tolerability. Sol-Gel has successfully developed two FDA-approved commercial products, TWYNEO® (for acne vulgaris) and EPSOLAY® (for inflammatory lesions of rosacea), both marketed in the United States by Galderma. The company's late-stage pipeline is led by SGT-610 (patidegib gel, 2%), a Phase 3 topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. Additionally, Sol-Gel is advancing SGT-210, an investigational topical EGFR inhibitor.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome.
Expected impact: Securing FDA approval for a breakthrough-designated topical hedgehog inhibitor with an improved safety profile relative to oral alternatives.
Establishing a commercial network for TWYNEO and EPSOLAY outside the United States through regional licensing and distribution partnerships.
Expected impact: Creating an annual royalty revenue stream projected to reach up to approximately $10 million by 2030 and further.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Sun Pharma will handle the commercialization of TWYNEO in India, expanding Sol-Gel's footprint into a major emerging market.
Terms: Specific financial terms were not disclosed, but the agreement contributes to the broader ex-U.S. milestone pool of up to $4.5 million.
Mayne Pharma acquired the U.S. commercial rights to EPSOLAY and TWYNEO, allowing Sol-Gel to monetize these legacy assets and focus resources on its rare disease pipeline.
Terms: Sol-Gel received a total of $16 million in two installments during 2025 ($10 million in Q2 2025 and $6 million in Q4 2025).
Viatris will commercialize TWYNEO and EPSOLAY in Australia and New Zealand, further building out the global commercial network.
Terms: Contributes to the ex-U.S. upfront and regulatory milestone payment pool.